Brief: Appili Submits Protocol For A Phase 3 Study Evaluating Favipiravir

Appili Therapeutics

11/09/2020 12:29

Sept 11 (Reuters) - Appili Therapeutics Inc  APLI.V :
    * APPILI SUBMITS PROTOCOL FOR A PHASE 3 STUDY EVALUATING
FAVIPIRAVIR FOR THE TREATMENT OF PATIENTS WITH COVID-19
INFECTIONS TO THE US FDA
    * APPILI THERAPEUTICS INC - INVESTIGATORS PLAN TO RECRUIT
826
PARTICIPANTS IN RANDOMIZED, PLACEBO-CONTROLLED TRIAL
    * APPILI THERAPEUTICS INC - COMMITTED TO EVALUATING USE OF
BROAD-SPECTRUM ANTIVIRAL IN EARLY TREATMENT SETTING OF COVID-19
    * APPILI THERAPEUTICS INC - EXPECTS TO INITIATE TRIAL
RECRUITMENT
FOR PHASE 3 STUDY IN FALL OF 2020

Source text for Eikon:  ID:nBwrL3K6a 
Further company coverage:  APLI.V 

 ((Reuters.Briefs@thomsonreuters.com;))